Acalculous cholecystitis associated with levodopa-carbidopa intestinal infusion therapy: A case report.

Continuous intra jejunal infusion of levodopa-carbidopa intestinal gel (LCIG) is one of the primary therapies for improving advanced Parkinson's disease symptoms. Placement of the jejunal catheter through the abdominal wall for drug administration requires a percutaneous interventional procedure called percutaneous endoscopic gastrostomy (PEG). PEG is considered a safe and straightforward procedure, and it is performed very commonly in clinical practice. In the context of LCIG treatment, severe adverse events have been identified, such as intestinal bleeding and acute abdomen [1], but acute acalculous cholecystitis (AAC) has never been reported.

© 2022 The Authors. Published by Elsevier Ltd.

Overview publication

TitleAcalculous cholecystitis associated with levodopa-carbidopa intestinal infusion therapy: A case report.
Date2022-01-01
Issue nameClinical parkinsonism & related disorders
Issue numberv7:100150
DOI10.1016/j.prdoa.2022.100150
PubMed35856047
AuthorsTorres V, González-Ortega G, Suárez A, Garrido A, Cámara A, Compta Y & Valldeoriola F
Read Read publication